Clinical perspectives of PSMA PET/MRI for prostate cancer
Clinics
;
73(supl.1): e586s, 2018. graf
Artículo
en Inglés
| LILACS
| ID: biblio-952840
ABSTRACT
Prostate cancer imaging has become an important diagnostic modality for tumor evaluation. Prostate-specific membrane antigen (PSMA) positron emission tomography (PET) has been extensively studied, and the results are robust and promising. The advent of the PET/magnetic resonance imaging (MRI) has added morphofunctional information from the standard of reference MRI to highly accurate molecular information from PET. Different PSMA ligands have been used for this purpose including 68gallium and 18fluorine-labeled PET probes, which have particular features including spatial resolution, imaging quality and tracer biodistribution. The use of PSMA PET imaging is well established for evaluating biochemical recurrence, even at low prostate-specific antigen (PSA) levels, but has also shown interesting applications for tumor detection, primary staging, assessment of therapeutic responses and treatment planning. This review will outline the potential role of PSMA PET/MRI for the clinical assessment of PCa.
Texto completo:
Disponible
Índice:
LILACS (Américas)
Asunto principal:
Neoplasias de la Próstata
/
Imagen por Resonancia Magnética
/
Glutamato Carboxipeptidasa II
/
Tomografía Computarizada por Tomografía de Emisión de Positrones
/
Antígenos de Superficie
Límite:
Humanos
/
Masculino
Idioma:
Inglés
Revista:
Clinics
Asunto de la revista:
Medicina
Año:
2018
Tipo del documento:
Artículo
País de afiliación:
Brasil
Institución/País de afiliación:
Hospital Sirio-Libanes/BR
Similares
MEDLINE
...
LILACS
LIS